Cytomx Therapeutics Stock Total Debt
| CTMX Stock | USD 1.06 0.04 3.92% |
CytomX Therapeutics fundamentals help investors to digest information that contributes to CytomX Therapeutics' financial success or failures. It also enables traders to predict the movement of CytomX Stock. The fundamental analysis module provides a way to measure CytomX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CytomX Therapeutics stock.
Total Debt To Capitalization is likely to rise to -0.4 in 2024. CytomX | Total Debt |
CytomX Therapeutics Company Total Debt Analysis
CytomX Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current CytomX Therapeutics Total Debt | 13.97 M |
Most of CytomX Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CytomX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CytomX Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for CytomX Therapeutics is extremely important. It helps to project a fair market value of CytomX Stock properly, considering its historical fundamentals such as Total Debt. Since CytomX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CytomX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CytomX Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
CytomX Total Debt Historical Pattern
Today, most investors in CytomX Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CytomX Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of CytomX Therapeutics total debt as a starting point in their analysis.
CytomX Therapeutics Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
CytomX Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, CytomX Therapeutics has a Total Debt of 13.97 M. This is 99.49% lower than that of the Biotechnology sector and 95.7% lower than that of the Health Care industry. The total debt for all United States stocks is 99.74% higher than that of the company.
CytomX Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytomX Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytomX Therapeutics could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics of similar companies.CytomX Therapeutics is currently under evaluation in total debt category among its peers.
CytomX Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of CytomX Therapeutics from analyzing CytomX Therapeutics' financial statements. These drivers represent accounts that assess CytomX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CytomX Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 376.7M | 302.3M | 277.8M | 105.2M | 114.4M | 108.7M | |
| Enterprise Value | 213.2M | 135.3M | 90.3M | (70.4M) | 111.2M | 105.6M |
CytomX Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in CytomX Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CytomX Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CytomX Therapeutics' value.| Shares | Rtw Investments, Llc | 2024-06-30 | 1.2 M | Blackrock Inc | 2024-06-30 | 1.1 M | Renaissance Technologies Corp | 2024-09-30 | 1 M | Altium Capital Management, Lp | 2024-09-30 | 915 K | Adar1 Capital Management Llc | 2024-09-30 | 904 K | Geode Capital Management, Llc | 2024-09-30 | 803.5 K | Two Sigma Investments Llc | 2024-09-30 | 471.5 K | Sei Investments Co | 2024-06-30 | 382.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 377 K | Tang Capital Management Llc | 2024-09-30 | 7.8 M | Hhg Plc | 2024-06-30 | 6.3 M |
CytomX Fundamentals
| Return On Equity | -54.75 | ||||
| Return On Asset | 0.0233 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | (27.17 M) | ||||
| Shares Outstanding | 78.26 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 65.62 % | ||||
| Number Of Shares Shorted | 4.44 M | ||||
| Price To Earning | (11.41) X | ||||
| Price To Book | 5.04 X | ||||
| Price To Sales | 0.63 X | ||||
| Revenue | 101.21 M | ||||
| Gross Profit | 53.16 M | ||||
| EBITDA | (4.31 M) | ||||
| Net Income | (569 K) | ||||
| Cash And Equivalents | 194.29 M | ||||
| Cash Per Share | 2.94 X | ||||
| Total Debt | 13.97 M | ||||
| Debt To Equity | 0.67 % | ||||
| Current Ratio | 2.05 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (56.03 M) | ||||
| Short Ratio | 4.41 X | ||||
| Earnings Per Share | 0.16 X | ||||
| Price To Earnings To Growth | (1.80) X | ||||
| Target Price | 5.29 | ||||
| Number Of Employees | 120 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 79.82 M | ||||
| Total Asset | 201.79 M | ||||
| Retained Earnings | (723.45 M) | ||||
| Working Capital | 27.02 M | ||||
| Current Asset | 189.75 M | ||||
| Current Liabilities | 15.74 M | ||||
| Net Asset | 201.79 M |
About CytomX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CytomX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytomX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytomX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.